Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NPY5R antagonism does not augment the weight loss efficacy of orlistat or sibutramine.
Erondu N, Addy C, Lu K, Mallick M, Musser B, Gantz I, Proietto J, Astrup A, Toubro S, Rissannen AM, Tonstad S, Haynes WG, Gottesdiener KM, Kaufman KD, Amatruda JM, Heymsfield SB. Erondu N, et al. Obesity (Silver Spring). 2007 Aug;15(8):2027-42. doi: 10.1038/oby.2007.242. Obesity (Silver Spring). 2007. PMID: 17712121 Free article. Clinical Trial.
A semi-mechanistic model for the effects of a novel glucagon receptor antagonist on glucagon and the interaction between glucose, glucagon, and insulin applied to adaptive phase II design.
Peng JZ, Denney WS, Musser BJ, Liu R, Tsai K, Fang L, Reitman ML, Troyer MD, Engel SS, Xu L, Stoch A, Stone JA, Kowalski KG. Peng JZ, et al. Among authors: musser bj. AAPS J. 2014 Nov;16(6):1259-70. doi: 10.1208/s12248-014-9648-x. Epub 2014 Aug 27. AAPS J. 2014. PMID: 25160589 Free PMC article. Clinical Trial.
Neuropeptide Y5 receptor antagonism does not induce clinically meaningful weight loss in overweight and obese adults.
Erondu N, Gantz I, Musser B, Suryawanshi S, Mallick M, Addy C, Cote J, Bray G, Fujioka K, Bays H, Hollander P, Sanabria-Bohórquez SM, Eng W, Långström B, Hargreaves RJ, Burns HD, Kanatani A, Fukami T, MacNeil DJ, Gottesdiener KM, Amatruda JM, Kaufman KD, Heymsfield SB. Erondu N, et al. Cell Metab. 2006 Oct;4(4):275-82. doi: 10.1016/j.cmet.2006.08.002. Cell Metab. 2006. PMID: 17011500 Free article. Clinical Trial.
Hypoglycaemia in sulphonylurea-treated subjects with type 2 diabetes undergoing Ramadan fasting: a five-country observational study.
Aravind SR, Al Tayeb K, Ismail SB, Shehadeh N, Kaddaha G, Liu R, Balshaw R, Lesnikova N, Heisel O, Girman CJ, Musser BJ, Davies MJ, Katzeff HL, Engel SS, Radican L; 2009 Ramadan Study Group. Aravind SR, et al. Among authors: musser bj. Curr Med Res Opin. 2011 Jun;27(6):1237-42. doi: 10.1185/03007995.2011.578245. Epub 2011 Apr 20. Curr Med Res Opin. 2011. PMID: 21506631
The incidence of hypoglycaemia in Muslim patients with type 2 diabetes treated with sitagliptin or a sulphonylurea during Ramadan: a randomised trial.
Al Sifri S, Basiounny A, Echtay A, Al Omari M, Harman-Boehm I, Kaddaha G, Al Tayeb K, Mahfouz AS, Al Elq A, Radican L, Ozesen C, Katzeff HL, Musser BJ, Suryawanshi S, Girman CJ, Davies MJ, Engel SS; 2010 Ramadan Study Group. Al Sifri S, et al. Among authors: musser bj. Int J Clin Pract. 2011 Nov;65(11):1132-40. doi: 10.1111/j.1742-1241.2011.02797.x. Epub 2011 Sep 27. Int J Clin Pract. 2011. PMID: 21951832 Free PMC article. Clinical Trial.
Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults.
Gantz I, Erondu N, Mallick M, Musser B, Krishna R, Tanaka WK, Snyder K, Stevens C, Stroh MA, Zhu H, Wagner JA, Macneil DJ, Heymsfield SB, Amatruda JM. Gantz I, et al. J Clin Endocrinol Metab. 2007 May;92(5):1754-7. doi: 10.1210/jc.2006-1806. Epub 2007 Mar 6. J Clin Endocrinol Metab. 2007. PMID: 17341568 Clinical Trial.
40 results